Response rates in FLT3-mutated AML patients treated with intensive chemotherapy are 51–54% with a median OS of 5.8 to 26 months [86,87], while treatment with venetoclax-based therapy resulted in CR/CRi rates ranging from 33% to 72% (Table 3) [31,37,38,39,40,41,48,54,88]. The gene discussed is FLT3; the disease is acute myeloid leukemia.